OBSERVATIONAL MULTICENTER TRIAL OF NICORANDIL USE IN STABLE CORONARY HEART DISEASE HIGH RISK PATIENTS (NIKEA): DESIGN AND FIRST RESULTS
| Autor: | S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, А. V. Akimova, V. P. Voronina, О. V. Lerman, О. V. Gaisenok, Т. А. Gomova, А. V. Ezhov, А. D. Kuimov, R. А. Libis, G. V. Matyushin, Т. N. Mitroshina, G. I. Nechaeva, I. I. Reznik, V. V. Skibitsky, L. А. Sokolova, А. I. Chesnikova, N. V. Dobrynina, S. S. Yakushin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Российский кардиологический журнал, Vol 0, Iss 9, Pp 75-82 (2017) |
| Druh dokumentu: | article |
| ISSN: | 1560-4071 2618-7620 |
| DOI: | 10.15829/1560-4071-2017-9-75-82 |
| Popis: | Aim. To assess the results of addition of nicorandil to the treatment of ischemic heart disease: clinical course and long-term outcomes, and to evaluate life quality and treatment adherence in stable angina patients. The article provides data on the NIKEA study design and results of antianginal efficacy of the drug.Material and methods. The design is prospective multicenter observational study. Totally, 14 institutions participated, from different Russia regions. Included 590 patients: 261 women (44,2%) and 329 men (55,8%). Mean age 65,1±9,6 y.o. All patients had inclusion criteria and no exclusion criteria. All participants, in addition to standard antianginal therapy, were recommended to take nicorandil dosage 20 mg daily with titration up to 40 mg daily in 1 month of the observation. By the protocol, three office visits were set (inclusion, in 1 month and in 3 months): V0, V1, V3. During the visits, physical examination was done, anthropometry, hemodynamics measurement. Antianginal efficacy was assessed with patients diaries on angina attacks and demand of short-acting nitrates (SAN). At the visits V0 and V3 patients completed Seattle life quality questionnaire in CHD, and at V0 also an original questionnaire was completed for adherence evaluation.Results. Among 590 patients included in NIKEA, 582 (98,6%) confirmed their intention to take nicorandil and 6 refused to buy additional medication. On the planned visits V1 and V3552 patients came: of them 402 started taking nicorandil, and in 1 month 383 continued; in 3 months — 327 patients continued. During the visits V1 and V3 a statistically significant decrease in angina attacks frequency and in demand of SAN was noted (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|